Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
With more food allergy treatments than ever — from oral immunotherapy to biologics — the real challenge isn't finding the "best" option, it's finding the right one for each patient. Dr. Douglas Jones argues that shared decision-making, patient goals, and life circumstances should drive treatment choices. One size definitely doesn't fit all.
Food allergy care has come a long way. Where clinicians once had little to offer beyond "avoid the allergen and carry an EpiPen," today's toolkit includes oral immunotherapy (OIT), sublingual immunotherapy (SLIT), biologics like omalizumab, and combination strategies. But more options don't automatically mean easier decisions — and allergist Dr. Douglas Jones says we've been asking the wrong question all along.
Instead of "which treatment is best?", Jones argues the real question is: which treatment is right for this patient, at this time, and for what purpose? A family hoping their child can eat peanuts freely has very different needs than one simply trying to stop worrying about trace exposures at a birthday party. Both goals are valid — and the treatment plan should reflect that.
Jones also cautions against physician bias, over-promising on outcomes, and mistaking complexity for quality. A protocol with more allergens, more visits, or a higher price tag isn't automatically better. True personalization means matching the approach to the patient's clinical profile, goals, risk tolerance, and life stage — and being willing to reassess as those factors evolve.
Key Takeaways:
Why it matters: As food allergy treatments multiply, so does the risk of defaulting to the most aggressive option rather than the most appropriate one. Centering shared decision-making and patient-defined success is key to sustainable, meaningful outcomes.
